SlideShare una empresa de Scribd logo
1 de 9
Descargar para leer sin conexión
www.BRIDGenomics.com
Bridging Gaps in Genomics
Professional Services for Advanced Molecular Testing
Maximize Your Return on Investment
BRIDGenomics helps clinical organizations develop and
commercialize genomic testing and maximize ROI.
Our highly experienced team can reduce your time to assay
commercialization by 75% and help you quickly grow revenue.
We’ve done this before and we can do it for you.
Quest Diagnostics
LabPMM Invivoscribe
Cancer Genetics Inc
BioGx
Geneuity
MPLN
Assay Commercialization
Typical NGS Assay Commercialization Timeline: 9 -18 months
Typical NGS Assay Commercialization Cost: $500k - $750k
These estimates exclude the cost of equipment
We routinely commercialize NGS-based LDTs in less than 3 months
BRIDGenomics average timeline includes: build out and staffing of lab space, as well as
commercialization of testing including state inspection/accreditation in under 90 days.
Experience Empowers
Our Team’s Selected Publications
This is why we routinely commercialize NGS-based LDTs in less than 3 months
Products Developed and Commercialized Projects supporting multiple sectors
Development and Validation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Variants for the Clinical Laboratory. 2015.
PLoS ONE 10(8): e0136419. doi:10.1371/journal.pone.0136419
A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-
Experienced Patients. 2012. PLoS ONE 7(9): e46334. doi:10.1371/journal.pone.0046334
CLSI. Nucleic Acid Sequencing Methods in Diagnostic Laboratory Medicine; Approved Guideline – Second Edition.
CLSI document MM09-A2. Wayne, PA. Clinical and Laboratory Standards Institute; 2014.
Depend on our Deep Domain Knowledge
More than 25 years of experience
▪ System, Product, and Assay development and validation
▪ High-Complexity Molecular Testing
▪ Emerging Technology Market Assessment
▪ Implementation of New Technologies
▪ PI on Clinical Studies for Pharma
▪ Invited Speaker
▪ Significant Patent Portfolio
More than 15 years of global industry experience in
molecular testing and NGS
▪ System, Product, and Assay Launch
▪ Wet bench and Bioinformatic Experienced
▪ SEAM Management Certified
▪ VOC, KOL and Market Development
▪ Focus Groups/Advisory Board Leader
▪ Significant Biomarker and Content Expertise
More than 15 years of clinical diagnostics experience
▪ Assay development, validation, & commercialization
▪ High-Complexity Molecular Testing
▪ Emerging Technology Market Assessment
▪ Implementation of New Technologies in Clinical Diagnostics
▪ Clinical Trials for Pharma and Device Manufacturers
▪ Genomics program development and pipeline strategies
▪ Strategic development and M & A’s
Jamie Platt, PhD, MB(ASCP)
CEO/Founder
Shawn Clairmont, MBA
Chief Operating Officer
Martin Siaw, PhD, MB(ASCP)
VP of Science & Innovation
Invited Speakers at the Liquid Biopsy Summit,
NextGen Dx Summit, Molecular Medicine TriConference….
Consulting & Partnering Services
Market
Strategy and
Development
Portfolio
Pipeline
Development
Genomics
Next Generation
Sequencing
Technology
Emerging
Technology
Development
LDT
Development
Process
Locum Tenens
Staffing and
Recruiting
Focus Group
&
Advisory Board
Informatics
Processes Pay Off
The Assay Commercialization Process
Examples of Completed Projects
Global Business Development
Build out (de novo)
Transition (low- to high-complexity)
Assay Pipeline Strategy Development
Validation Guidance
NGS Technical Expertise
Workflow and Automation
Customization
Regulatory
CAP accreditation
CLIA certification
NYS CLEP
ISO 15189
ISO 13485
California DFS
COLA
Pharma + Service Provider
Device Co. + Technology Co.
Lab + Tools Provider
Service Provider + Software Co.
Lab + Lab
Strategic Marketing
Market Assessment
Content Marketing
Focus Groups
Advisory Boards
White Papers
Laboratory
Sales and Marketing
More than Information… Solutions
We’d love to connect with you!
info@BRIDGenomics.com
949-244-2591

Más contenido relacionado

Destacado

2.21.17 exas corporate presentation - final
2.21.17   exas corporate presentation - final2.21.17   exas corporate presentation - final
2.21.17 exas corporate presentation - finalExact Sciences
 
J Rios Resume - Commercial - Jan - 2016
J Rios Resume - Commercial - Jan - 2016J Rios Resume - Commercial - Jan - 2016
J Rios Resume - Commercial - Jan - 2016Jose Rios
 
Presentación sobre slide share
Presentación sobre slide sharePresentación sobre slide share
Presentación sobre slide sharecamila_vc1
 
Martian Manhunter
Martian ManhunterMartian Manhunter
Martian Manhunter1x126737
 
10.01.2017 Michele Boyley CV
10.01.2017  Michele Boyley CV10.01.2017  Michele Boyley CV
10.01.2017 Michele Boyley CVMichele Boyley
 
Acuerdo 47 2008-firmas_electrónicas
Acuerdo 47 2008-firmas_electrónicasAcuerdo 47 2008-firmas_electrónicas
Acuerdo 47 2008-firmas_electrónicasisabel merida
 
Rusume of Engr. Pasha
Rusume of Engr. PashaRusume of Engr. Pasha
Rusume of Engr. PashaArif Siddiki
 
John_Sheehan 110816
John_Sheehan 110816John_Sheehan 110816
John_Sheehan 110816John Sheehan
 

Destacado (12)

2.21.17 exas corporate presentation - final
2.21.17   exas corporate presentation - final2.21.17   exas corporate presentation - final
2.21.17 exas corporate presentation - final
 
Mike CV updated
Mike CV updatedMike CV updated
Mike CV updated
 
J Rios Resume - Commercial - Jan - 2016
J Rios Resume - Commercial - Jan - 2016J Rios Resume - Commercial - Jan - 2016
J Rios Resume - Commercial - Jan - 2016
 
Class 10 hindi
Class 10 hindiClass 10 hindi
Class 10 hindi
 
Presentación sobre slide share
Presentación sobre slide sharePresentación sobre slide share
Presentación sobre slide share
 
Martian Manhunter
Martian ManhunterMartian Manhunter
Martian Manhunter
 
Company Profile(1)
Company Profile(1)Company Profile(1)
Company Profile(1)
 
10.01.2017 Michele Boyley CV
10.01.2017  Michele Boyley CV10.01.2017  Michele Boyley CV
10.01.2017 Michele Boyley CV
 
Acuerdo 47 2008-firmas_electrónicas
Acuerdo 47 2008-firmas_electrónicasAcuerdo 47 2008-firmas_electrónicas
Acuerdo 47 2008-firmas_electrónicas
 
Rusume of Engr. Pasha
Rusume of Engr. PashaRusume of Engr. Pasha
Rusume of Engr. Pasha
 
Puppet show
Puppet showPuppet show
Puppet show
 
John_Sheehan 110816
John_Sheehan 110816John_Sheehan 110816
John_Sheehan 110816
 

Similar a BRIDGenomics Intro & Summary of Services_Jan2017

pc15222_brochure
pc15222_brochurepc15222_brochure
pc15222_brochureAmy Ripston
 
Tbi Bioprocessing Services Sept 25.08
Tbi Bioprocessing Services Sept 25.08Tbi Bioprocessing Services Sept 25.08
Tbi Bioprocessing Services Sept 25.08Thomas Wellner
 
Hem syngene 24_july_2015
Hem syngene 24_july_2015Hem syngene 24_july_2015
Hem syngene 24_july_2015IndiaNotes.com
 
GMP COMPLIANCE BROCHURE
GMP COMPLIANCE BROCHUREGMP COMPLIANCE BROCHURE
GMP COMPLIANCE BROCHUREGiby George
 
Updated capabilities overview1
Updated  capabilities overview1Updated  capabilities overview1
Updated capabilities overview1malbergo
 
Biodextris Presentation - New client presentation
Biodextris Presentation - New client presentationBiodextris Presentation - New client presentation
Biodextris Presentation - New client presentationJoseph Zimmermann
 
Sai pharma consultants
Sai pharma consultantsSai pharma consultants
Sai pharma consultantsT Rama Rao
 
Charlie Coco Resume Director of Quality
Charlie Coco Resume Director of Quality Charlie Coco Resume Director of Quality
Charlie Coco Resume Director of Quality Charlie Coco
 
3716_A5_Capabilities_Brochure_R7
3716_A5_Capabilities_Brochure_R73716_A5_Capabilities_Brochure_R7
3716_A5_Capabilities_Brochure_R7Catharine S
 
PCT Presentation Shared October 2016
PCT Presentation Shared October 2016PCT Presentation Shared October 2016
PCT Presentation Shared October 2016Cenk Sumen
 
Cost-Effective Clinical Development with Strategic Clinical Innovation Organi...
Cost-Effective Clinical Development with Strategic Clinical Innovation Organi...Cost-Effective Clinical Development with Strategic Clinical Innovation Organi...
Cost-Effective Clinical Development with Strategic Clinical Innovation Organi...BBCR Consulting
 
GVK BIO Corporate Brochure 2017
GVK BIO Corporate Brochure 2017 GVK BIO Corporate Brochure 2017
GVK BIO Corporate Brochure 2017 GVK Biosciences
 
MEDWIZE SOLUTIONS_e- Brochure
MEDWIZE SOLUTIONS_e- BrochureMEDWIZE SOLUTIONS_e- Brochure
MEDWIZE SOLUTIONS_e- BrochureMedWize Solutions
 
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Yavuz Silay
 
Six sigma and pharmaceutical industry4
Six sigma and pharmaceutical industry4Six sigma and pharmaceutical industry4
Six sigma and pharmaceutical industry4DrAbdulaziz Saddique
 
The high stakes of running an oncology clinical trial
The high stakes of running an oncology clinical trialThe high stakes of running an oncology clinical trial
The high stakes of running an oncology clinical trialDavid Levin
 

Similar a BRIDGenomics Intro & Summary of Services_Jan2017 (20)

pc15222_brochure
pc15222_brochurepc15222_brochure
pc15222_brochure
 
Tbi Bioprocessing Services Sept 25.08
Tbi Bioprocessing Services Sept 25.08Tbi Bioprocessing Services Sept 25.08
Tbi Bioprocessing Services Sept 25.08
 
Hem syngene 24_july_2015
Hem syngene 24_july_2015Hem syngene 24_july_2015
Hem syngene 24_july_2015
 
GMP COMPLIANCE BROCHURE
GMP COMPLIANCE BROCHUREGMP COMPLIANCE BROCHURE
GMP COMPLIANCE BROCHURE
 
Updated capabilities overview1
Updated  capabilities overview1Updated  capabilities overview1
Updated capabilities overview1
 
Progamma Us
Progamma UsProgamma Us
Progamma Us
 
Biodextris Presentation - New client presentation
Biodextris Presentation - New client presentationBiodextris Presentation - New client presentation
Biodextris Presentation - New client presentation
 
Stability Dosage-Development-Presentation
Stability Dosage-Development-PresentationStability Dosage-Development-Presentation
Stability Dosage-Development-Presentation
 
Sai pharma consultants
Sai pharma consultantsSai pharma consultants
Sai pharma consultants
 
Charlie Coco Resume Director of Quality
Charlie Coco Resume Director of Quality Charlie Coco Resume Director of Quality
Charlie Coco Resume Director of Quality
 
3716_A5_Capabilities_Brochure_R7
3716_A5_Capabilities_Brochure_R73716_A5_Capabilities_Brochure_R7
3716_A5_Capabilities_Brochure_R7
 
PCT Presentation Shared October 2016
PCT Presentation Shared October 2016PCT Presentation Shared October 2016
PCT Presentation Shared October 2016
 
Cost-Effective Clinical Development with Strategic Clinical Innovation Organi...
Cost-Effective Clinical Development with Strategic Clinical Innovation Organi...Cost-Effective Clinical Development with Strategic Clinical Innovation Organi...
Cost-Effective Clinical Development with Strategic Clinical Innovation Organi...
 
NeoGenomics Company Overview 2.22.16
NeoGenomics Company Overview 2.22.16NeoGenomics Company Overview 2.22.16
NeoGenomics Company Overview 2.22.16
 
GVK BIO Corporate Brochure 2017
GVK BIO Corporate Brochure 2017 GVK BIO Corporate Brochure 2017
GVK BIO Corporate Brochure 2017
 
MEDWIZE SOLUTIONS_e- Brochure
MEDWIZE SOLUTIONS_e- BrochureMEDWIZE SOLUTIONS_e- Brochure
MEDWIZE SOLUTIONS_e- Brochure
 
Stabicon Corporate Presentation
Stabicon Corporate PresentationStabicon Corporate Presentation
Stabicon Corporate Presentation
 
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...
 
Six sigma and pharmaceutical industry4
Six sigma and pharmaceutical industry4Six sigma and pharmaceutical industry4
Six sigma and pharmaceutical industry4
 
The high stakes of running an oncology clinical trial
The high stakes of running an oncology clinical trialThe high stakes of running an oncology clinical trial
The high stakes of running an oncology clinical trial
 

BRIDGenomics Intro & Summary of Services_Jan2017

  • 1. www.BRIDGenomics.com Bridging Gaps in Genomics Professional Services for Advanced Molecular Testing
  • 2. Maximize Your Return on Investment BRIDGenomics helps clinical organizations develop and commercialize genomic testing and maximize ROI. Our highly experienced team can reduce your time to assay commercialization by 75% and help you quickly grow revenue. We’ve done this before and we can do it for you. Quest Diagnostics LabPMM Invivoscribe Cancer Genetics Inc BioGx Geneuity MPLN
  • 3. Assay Commercialization Typical NGS Assay Commercialization Timeline: 9 -18 months Typical NGS Assay Commercialization Cost: $500k - $750k These estimates exclude the cost of equipment We routinely commercialize NGS-based LDTs in less than 3 months BRIDGenomics average timeline includes: build out and staffing of lab space, as well as commercialization of testing including state inspection/accreditation in under 90 days.
  • 4. Experience Empowers Our Team’s Selected Publications This is why we routinely commercialize NGS-based LDTs in less than 3 months Products Developed and Commercialized Projects supporting multiple sectors Development and Validation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Variants for the Clinical Laboratory. 2015. PLoS ONE 10(8): e0136419. doi:10.1371/journal.pone.0136419 A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment- Experienced Patients. 2012. PLoS ONE 7(9): e46334. doi:10.1371/journal.pone.0046334 CLSI. Nucleic Acid Sequencing Methods in Diagnostic Laboratory Medicine; Approved Guideline – Second Edition. CLSI document MM09-A2. Wayne, PA. Clinical and Laboratory Standards Institute; 2014.
  • 5. Depend on our Deep Domain Knowledge More than 25 years of experience ▪ System, Product, and Assay development and validation ▪ High-Complexity Molecular Testing ▪ Emerging Technology Market Assessment ▪ Implementation of New Technologies ▪ PI on Clinical Studies for Pharma ▪ Invited Speaker ▪ Significant Patent Portfolio More than 15 years of global industry experience in molecular testing and NGS ▪ System, Product, and Assay Launch ▪ Wet bench and Bioinformatic Experienced ▪ SEAM Management Certified ▪ VOC, KOL and Market Development ▪ Focus Groups/Advisory Board Leader ▪ Significant Biomarker and Content Expertise More than 15 years of clinical diagnostics experience ▪ Assay development, validation, & commercialization ▪ High-Complexity Molecular Testing ▪ Emerging Technology Market Assessment ▪ Implementation of New Technologies in Clinical Diagnostics ▪ Clinical Trials for Pharma and Device Manufacturers ▪ Genomics program development and pipeline strategies ▪ Strategic development and M & A’s Jamie Platt, PhD, MB(ASCP) CEO/Founder Shawn Clairmont, MBA Chief Operating Officer Martin Siaw, PhD, MB(ASCP) VP of Science & Innovation Invited Speakers at the Liquid Biopsy Summit, NextGen Dx Summit, Molecular Medicine TriConference….
  • 6. Consulting & Partnering Services Market Strategy and Development Portfolio Pipeline Development Genomics Next Generation Sequencing Technology Emerging Technology Development LDT Development Process Locum Tenens Staffing and Recruiting Focus Group & Advisory Board Informatics
  • 7. Processes Pay Off The Assay Commercialization Process
  • 8. Examples of Completed Projects Global Business Development Build out (de novo) Transition (low- to high-complexity) Assay Pipeline Strategy Development Validation Guidance NGS Technical Expertise Workflow and Automation Customization Regulatory CAP accreditation CLIA certification NYS CLEP ISO 15189 ISO 13485 California DFS COLA Pharma + Service Provider Device Co. + Technology Co. Lab + Tools Provider Service Provider + Software Co. Lab + Lab Strategic Marketing Market Assessment Content Marketing Focus Groups Advisory Boards White Papers Laboratory Sales and Marketing
  • 9. More than Information… Solutions We’d love to connect with you! info@BRIDGenomics.com 949-244-2591